Grant

  1. Showing 72 results for:
  2. Funding
  3. Public
  4. Grant
All Subjects

Ultra-Rare Gene-based Therapy (URGenT) Network Resource Access

Published by NIH

CMOContract Medical OrganizationContract Research OrganizationCRO

The purpose of this FOA is to provide investigators with a mechanism to access contract research/medical organizations (CROs/CMOs) and subject matter experts (SMEs) within the NINDS Ultra-Rare Gene-based Therapy (URGenT) Network to support planning, manufacturing, and limited nonclinical therapeutic development efforts.

View this resource Bookmark this resource

Critical Path Public Private Partnerships

Published by NIH

Research Demonstration Cooperative Agreements

The FDA seeks an application to continue to maintain, manage existing consortia groups convened and established by the Critical Path Institute. This is a renewal of the cooperative agreement #5U18FD005320 as part of the Critical Path Initiative. This is in support of Critical Path Initiative introduced in Section 566 of the Federal Food, Drug, and Cosmetic Act. This includes developing innovative, collaborative projects in research, education, and outreach for fostering drug product innovation, enabling the acceleration of development, manufacturing, and translational therapeutics, enhancing safety, efficacy, quality, and performance. This funding opportunity will provide support, depending on availability of FDA funding.

View this resource Bookmark this resource

NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required)

Published by NIH

and Fast-TrackPhase IISmall Business Innovation Research (SBIR) Grant - Phase I

The purpose of this notice of funding opportunity (NOFO) is to provide a vehicle for Small Business Concerns (SBCs) submitting Small Business Innovation Research (SBIR) grant applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The projects must focus on products related to the mission and goals of the NINDS and may evaluate drugs, biologics, devices, or diagnostics, as well as surgical, behavioral or rehabilitation therapies.

View this resource Bookmark this resource

Cellular and Molecular Biology of Complex Brain Disorders

Published by NIH

Exploratory/Developmental Research Grant

This Notice of Funding Opportunity (NOFO) encourages research on the biology of high confidence risk factors associated with complex brain disorders, with a focus on the intracellular, transcellular and circuit substrates of neural function. For the purposes of this NOFO , the term “complex” can refer to a multifactorial contribution to risk (e.g., polygenic and/or environmental) and/or highly distributed functional features of the brain disorders

View this resource Bookmark this resource

Limited Competition: Small Grant Program for the NCATS Clinical and Translational Science Award

Published by NIH

Small Grant Program

The purpose of this NOFO is to enhance the capability of NCATS CTSA Program KL2/K12 scholars and recipients of diversity and re-entry supplements (Research Supplements to Promote Diversity in Health-Related Research (Admin Supp – Clinical Trial Not Allowed) (PA-23-189 and PA-21-071)) and Research Supplements to Promote Re-Entry, Re-integration into, and Re-training in Health-Related Research Careers (Admin Supp – Clinical Trial Not Allowed) (NOT-OD-23-170 and NOT-OD-21-134)) supported by the CTSA Program to conduct translational science research as they complete the transition to fully independent academic translational scientists.

View this resource Bookmark this resource

Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders

Published by NIH

Research Project Cooperative Agreements

The Ultra-Rare Gene-Based Therapy (URGenT) network supports Investigational New Drug (IND)-enabling studies and planning activities for First-in-Human (FIH) clinical testing of gene-based or transcript-directed therapeutics, such as oligonucleotides and viral-based gene therapies, for ultra-rare neurological or neuromuscular disorders. The goal of this funding opportunity announcement (FOA) is to accelerate the development of a promising clinical candidate with robust biological rationale and demonstrated proof of concept (POC) data for the intended approach in a model system relevant to a specified patient population towards an IND filing and the initiation of a clinical trial.

View this resource Bookmark this resource

MSCA COFUND 2024

Published by European Commission (EC)

COFUNDMSCA

Applicants submit proposals for new or existing doctoral or postdoctoral programmes with an impact on the enhancement of human resources in R&I at regional, national or international level. These programmes will be co-funded by MSCA COFUND.

Proposed programmes can cover any research disciplines (“bottom-up”), but exceptionally can also focus on specific disciplines, notably when they are based on national or regional Research and Innovation Strategies for Smart Specialisation (RIS3 strategies). In this case, the range of covered disciplines should allow reasonable flexibility for the researchers to define their topic.

Funding synergies with Cohesion policy funds and the Recovery and Resilience Facility (RRF) are strongly encouraged[1],[2].

A Career Development Plan must be jointly established by the supervisor and each recruited researcher upon recruitment. In addition to research objectives, this Plan comprises the researcher’s training and career needs, including training on transferable skills, teaching, planning for publications and participation in conferences and events aimed at opening science and research to citizens. The Plan must be established at the beginning of the recruitment and should be revised (and updated where needed) within 18 months.

View this resource Bookmark this resource

MSCA Doctoral Networks 2024

Published by European Commission (EC)

Doctoral NetworkMSCA

MSCA Doctoral Networks will implement doctoral programmes, by partnerships of universities, research institutions and research infrastructures, businesses including SMEs, and other socio-economic actors from different countries across Europe and beyond. MSCA Doctoral Networks are indeed open to the participation of organisations from third countries, in view of fostering strategic international partnerships for the training and exchange of researchers.

These doctoral programmes will respond to well-identified needs in various R&I areas, expose the researchers to the academic and non-academic sectors, and offer training in research-related, as well as transferable skills and competences relevant for innovation and long-term employability (e.g. entrepreneurship, commercialisation of results, Intellectual Property Rights, communication). Proposals for doctoral networks can reflect existing or planned research partnerships among the participating organisations.

The selection procedure for doctoral candidates must be open, transparent and merit-based, in line with the Code of Conduct for the Recruitment of Researchers. The vacancy notice (to be widely advertised internationally, including on the EURAXESS website) must mention if the published rates include all employer and employee’s taxes and contributions. If possible, the gross salary (net salary + employee’s taxes and contributions) should be published.

MSCA Doctoral Networks are encouraged to lead to Industrial or Joint Doctorates.

View this resource Bookmark this resource

MSCA Postdoctoral Fellowships 2024

Published by European Commission (EC)

Fellowship

Fellowships will be provided to excellent researchers undertaking international mobility. Applications will be made jointly by the researcher and a beneficiary in the academic or non-academic sector.

Postdoctoral Fellowships either can take place in Europe (i.e. in an EU Member State or a Horizon Europe Associated Country) or in a Third Country not associated to Horizon Europe:

View this resource Bookmark this resource